NICE recommends treatments for rare form of colorectal cancer

pharmafile | June 14, 2021 | News story | Sales and Marketing  

NICE has recommended BMS’s nivolumab plus ipilimumab (also known as Opdivo and Yervoy) to treat people with a rare form of colorectal cancer.

The treatments will be used to help people with metastatic colorectal cancer with high microsatellite instability (MSI) or mismatch repair (MMR) deficiency after fluoropyrimidine-based combination chemotherapy.

High MSI or MMR deficiency occurs in around 4% of metastatic colorectal cancer patients. Colorectal cancer with high MSI or MMR deficiency is associated with a poorer prognosis and a greater risk of death than colorectal cancer without these mutations.

Clinical trial evidence suggests that nivolumab plus ipilimumab may extend how long people live.

The most relevant trial did not directly compare nivolumab plus ipilimumab with usual treatments, but indirect comparisons suggest that it substantially increases how long it takes for the cancer to get worse and how long people live.

The NICE recommendation is based on data from the ongoing Phase II Checkmate-142 study, which showed that the combination of nivolumab plus ipilimumab can potentially offer long progression-free survival and overall survival.

An objective response rate of 65% after a follow up period of 51 months was seen with the combination treatment.

The decision from NICE offers a new treatment option for patients with bowel cancer after chemotherapy has failed, for whom there are currently limited treatment options.

Genevieve Edwards, Chief Executive at Bowel Cancer UK, said: “Advanced bowel cancer with the rare MSI-H/dMMR mutation can be difficult to treat.

“If chemotherapy fails then this patient population has had limited treatment options, so we welcome the NICE decision to make this combination of nivolumab with ipilimumab available to them.”

Dr Hubert Bland, Executive Medical Director UK and Ireland, Bristol Myers Squibb, said: “At Bristol Myers Squibb we are committed to bringing our innovative medicines to patients across the UK and Ireland.

“We are grateful to the hospitals and patients involved in the trials that have helped bring this immunotherapy combination to patients with advanced bowel cancer.”

Lilly Subbotin

Related Content

No items found

Latest content